Reply to: “A novel three dimensional imaging method for the measurement of area in vitiligo and chemical leukoderma”

We read with great interest the recent letter by Hayashi et al. describing three dimensional (3D) imaging in vitiligo and chemical leukoderma [1]. We acknowledge their conclusion that the VECTRA® H1 device offers an efficient and accurate method to objectively assess vitiligo and chemical leukoderma, however feel that an inadequate review of the literature was performed. We acknowledge that there is a paucity of evidence to substantiate the use of 3D imaging in diseases of skin hypopigmentation, and we would like to highlight the letter in Experimental Dermatology that investigated 3D imaging of vitiligo using the Canfield Vectra Whole Body 360 (WB360) [2].